Innoviva, Inc. (INVA) Stock Analysis
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $22.84, but acceptable to hold if already in. Reasons: Concentration risk — Counterparty: GSK; Earnings expected to decline ~65% (cyclical peak).
Innoviva is a diversified biopharmaceutical company with a royalty portfolio from GSK partnerships (RELVAR/BREO ELLIPTA and ANORO ELLIPTA for COPD/asthma) plus an infectious disease commercial platform (GIAPREZA, XACDURO, XERAVA, ZEVTERA, NUZOLVENCE). Near-term revenues are... Read more
Hold if already holding. Not a fresh buy at $22.84, but acceptable to hold if already in. Reasons: Concentration risk — Counterparty: GSK; Earnings expected to decline ~65% (cyclical peak). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Score 6.5/10, moderate confidence.
Passes 6/7 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 86d clear, semi cycle peak clear). Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHcounterpartyGSK10-K Item 1A: 'currently, we derive the majority of our revenues from GSK and our near-term success depends in large part on GSK's ability to successfully develop and commercialize the products in the respiratory programs partnered with GSK.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 ceiling hit
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $22.84, but acceptable to hold if already in. Reasons: Concentration risk — Counterparty: GSK; Earnings expected to decline ~65% (cyclical peak). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Target $30.80 (+34.9%), stop $21.61 (−5.7%), A.R:R 6.2:1. Score 6.5/10, moderate confidence.
Take-profit target: $30.80 (+34.6% upside). Target $30.80 (+34.9%), stop $21.61 (−5.7%), A.R:R 6.2:1. Stop-loss: $21.61.
Concentration risk — Counterparty: GSK; Earnings expected to decline ~65% (cyclical peak).
Innoviva, Inc. trades at a P/E of 3.7 (forward 10.4). TrendMatrix value score: 9.0/10. Verdict: Hold.
11 analysts cover INVA with a consensus score of 4.1/5. Average price target: $35.
What does Innoviva, Inc. do?Innoviva is a diversified biopharmaceutical company with a royalty portfolio from GSK partnerships (RELVAR/BREO ELLIPTA...
Innoviva is a diversified biopharmaceutical company with a royalty portfolio from GSK partnerships (RELVAR/BREO ELLIPTA and ANORO ELLIPTA for COPD/asthma) plus an infectious disease commercial platform (GIAPREZA, XACDURO, XERAVA, ZEVTERA, NUZOLVENCE). Near-term revenues are majority GSK royalties; IST commercial products are growing. Headquartered in Burlingame, CA.